GEN Exclusives

More »

GEN News Highlights

More »
Apr 19, 2007

BioFocus DPI and AstraZeneca Sign Second Discovery Transaction

  • BioFocus DPI entered into a drug discovery collaboration with AstraZeneca. This is the second program between the two companies after the August 2006 agreement.

    In this new deal, BioFocus DPI will perform medicinal chemistry, computational chemistry, and supporting biology and ADME-Tox services for an AstraZeneca drug discovery program. Total contract value for Galapagos is Euro 620,000.

    "We have been pleased with the level of progress thus far and expect that BioFocus DPI's expanded ADMET and predictive drug discovery capabilities will be key contributors in advancing this hit-to-lead program," says Lars-Erik Arvidsson, vp, head of respiratory research, AstraZeneca R&D Lund.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?